本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
NEW YORK, May 27, 2024 /PRNewswire/ -- Aquaron Acquisition Corp. (NASDAQ: AQU, the "Company"), a special purpose acquisition company, announced today that on May 22, the Company received a written notice (the "Notice") from the Listing Qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it currently does not satisfy Listing Rule 5250(c)(1), as a result of not having timely filed with the U.S. Securities and Exchange Commission (the "Commission") its Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"). The Notice is a notification of deficiency, not of imminent delisting, and has no immediate effect on the listing or trading of the Company's securities on the Nasdaq Capital Market. The Company has 60 calendar days from the date of the Notice, or until July 22, 2024, to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule 5250(c)(1). If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the due date of the filing of the Form 10-Q, or until November 18, 2024, to regain compliance. If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company's common stock will be subject to delisting. The Company would then be entitled to appeal that determination to a Nasdaq hearings panel. The Company's objective is to regain compliance with the listing requirement, and the Company currently intends to file the Form 10-Q with the Commission as soon as it completes the preparation and review of its financial statements for the period ended March 31, 2024. About Aquaron Acquisition Corp. Aquaron Acquisition Corp. is a Delaware corporation incorporated as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although it intends to focus on operating businesses in the new energy sector. The Company affirmatively excludes as an initial business combination target any company of which financial statements are audited by an accounting firm that the United States Public Company Accounting Oversight Board is unable to inspect for two consecutive years beginning in 2021 and any target company with China operations consolidated through a VIE structure. Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
NEW YORK, May 27, 2024 /PRNewswire/ -- IFF (NYSE: IFF), a global leader in food and beverage, home and personal care and health will unveil groundbreaking study results at upcoming major biomedical conferences. These results highlight how IFF Pharma Solutions NovaMatrix® portfolio of ultrapure alginate biopolymers could revolutionize regenerative medicine and 3D cell culture applications. At the 12th World Biomaterials Congress (WBC), IFF Pharma Solutions will showcase a first-of-its-kind alginate hydrogel system that self-gels, offering a minimally invasive way to deliver therapeutics. The company will then reveal how its unique porous alginate foam scaffolds can be utilized for 3D cell culture at the TERMIS World Congress. Breakthrough alginate hydrogel system in the spotlight at WBC At WBC in Daegu, South Korea, May 26-31, booth #74, visitors will learn how IFF is breaking boundaries in the biotech space with novel alginate biopolymer technologies. During a poster session on May 28 at 06:00 PM (Korean standard time), Caroline Cooreman, global business development & product manager, Biotechnology, IFF Pharma Solutions, will reveal groundbreaking alginate hydrogel system that self-gels within minutes after injection. This is enabled by combining a calcium alginate suspension with soluble sodium alginate. The resulting self-gelling hydrogel system could transform regenerative medicine by providing a minimally invasive alternative to surgical implantation procedures for delivering therapeutic cells, proteins, or drugs. "Our revolutionary self-gelling technology is just one aspect of our alginate innovation that we're illuminating at WBC," said Caroline Cooreman. "Through our unmatched polymer expertise and rigorous research, we understand how to tailor the viscosity and strength of our alginate gels by selecting specific alginate monomer compositions and molecular weights. This allows us to create custom gels optimized for our customers' unique formulation needs." Pioneering alginate foam scaffolds to be featured at TERMIS IFF will continue its alginate innovation showcase just weeks later at the 7th TERMIS World Congress in Seattle, Washington, June 25-28. Mark Dreibelbis, senior scientist, IFF Pharma Solutions, will reveal pioneering macro-porous alginate foam scaffolds for 3D cell culture on Wednesday June 26, at 7:05 PM PDT in Hall 4A with a follow-up on Thursday, June 27, at 6:15 PM PDT in Hall 4A. The presentation titled, Macroporous Alginate Foam Scaffolds for 3D Cell Growth will be part of the theater and poster sessions at the conference. Leveraging its deep expertise in alginates and customization capabilities, IFF has tuned the foam scaffolds to achieve 3D culture conditions for various cell types based on customer needs. By offering practical methods for cell seeding and release, the alginate foams offer a non-animal-based cell culture environment which could support tissue engineering and therapeutic screening applications. "As the only supplier of ultrapure and sterile alginates, we're excited about how our industry leading NovaMatrix® portfolio is propelling the biotech field forward," added Caroline. "The latest research we're revealing at WBC and TERMIS will provide our customers with transformative solutions for next-generation biotherapeutics – from controlled hydrogel technologies to advanced 3D cell culture platforms. Looking ahead, we will continue to actively research and advance the impact that our high-quality alginate polymers can bring to further support our customers in the biomedical industry." For more information about IFF's industry-leading portfolio of ultrapure NovaMatrix® biopolymers, visit IFF Pharma Solutions and stop by at either of IFF's upcoming events or tune in to our June 5 webinar, "Advancing cell therapy: innovations in polymer-based encapsulation and delivery". Register here. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, X (Twitter) , Facebook, Instagram, and LinkedIn. ©2024 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with TM, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved. Contact:Reena ChaudharyGlobal Communications Manager+91 9769820494reena.chaudhary@iff.com
Highlights: Statistically significant improvement from baseline assessed by both clinicians and caregivers in all four efficacy measures specifically designed for Pitt Hopkins syndrome (Wilcoxon signed rank test p<0.05) Clinician and caregiver global efficacy measures showed a level of improvement considered clinically meaningful: - Clinical Global Impression of Improvement (CGI-I) - mean score of 2.6, with 9 out of 11 children showing improvement assessed by clinicians- Caregiver Overall Impression of Change (CIC) – mean score of 3.0, with 8 out of 11 children showing improvement assessed by caregivers Improvements were seen in clinically important aspects of Pitt Hopkins syndrome, including communication, social interaction, cognition and motor abilities NNZ-2591 was safe and well tolerated, with no serious or severe adverse events and no meaningful trends in laboratory values or other safety parameters during treatment Second positive Phase 2 trial result further strengthens confidence in NNZ-2591's potential relevance for multiple neurodevelopmental disorders MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all 4 efficacy measures that were specifically designed to assess the core characteristics of PTHS. There are no approved treatments for PTHS despite its severely debilitating impact on the lives of patients, as well as their parents and siblings. Neuren CEO Jon Pilcher commented "We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need and we can now continue towards our goal of developing a first approved treatment. We are very grateful to the people in the Pitt Hopkins community and at the trial sites in the United States who enabled the successful completion of this extremely challenging, but groundbreaking trial." Elliott Sherr, M.D., Ph.D., Professor of Neurology and Pediatrics at the University of California San Francisco, and Director, Brain Development Research Program was an investigator in the trial. Dr Sherr commented: "I am optimistic about the results in the PTHS specific measures. The mechanism of action of NNZ-2591 supports this response seen in PTHS and its potential in other highly impactful neurodevelopmental disorders." Dr. Nancy Jones, Neuren Vice President of Clinical Development commented: "The consistent results on the PTHS specific assessments affirm the need for syndrome specific measurements in severe neurodevelopmental disorders where measures that were developed for broader populations may not be as appropriate. Neuren appreciates the collaboration of Dr. Cassandra Newsom, Associate Professor at the University of Alabama, Birmingham (an investigator in the trial), the Pitt-Hopkins Research Foundation, and others who contributed to the development of these important measures." Study design The open label Phase 2 trial in 16 children aged 3 to 17 years (mean age 9 years) at five hospitals in the United States examined safety, tolerability, pharmacokinetics and efficacy over 13 weeks of treatment with NNZ-2591. NNZ-2591 was administered to all subjects as an oral liquid dose twice daily, with escalation in two stages up to the target dose of 12 mg/kg during the first 6 weeks of treatment, subject to independent review of safety and tolerability data. The study commenced with at least 4 weeks of screening and observation to thoroughly define baseline characteristics prior to treatment, followed by the treatment period of 13 weeks. A follow-up assessment was made 2 weeks after the end of treatment. The primary endpoints of this first trial in children with PTHS were safety, tolerability and pharmacokinetics. Secondary endpoints included four efficacy measures specifically designed for PTHS assessed by clinicians and by caregivers, as well as ten efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. Safety and tolerability NNZ-2591 was well tolerated and demonstrated a good safety profile. All Treatment Emergent Adverse Events (TEAEs) were mild to moderate and most were considered not related to study drug. There were no Serious TEAEs and no meaningful trends in laboratory values, electrocardiogram (ECG) or other safety parameters were observed during treatment. 11 subjects completed the trial. One subject discontinued because they were unable to complete the safety monitoring procedures required by the study protocol. Four subjects discontinued due to TEAEs, all of which resolved. For two of those subjects the TEAEs (COVID-19 and mild vomiting/diarrhea/lethargy) were considered not related to study drug and for two subjects the TEAEs (moderate constipation/self-injury/abdominal distention/fatigue and mild sleep disorder/constipation) were considered related to study drug. Efficacy The mean improvement from baseline was statistically significant (Wilcoxon signed rank test p<0.05) for each of the four efficacy measures that were specifically designed for Pitt Hopkins syndrome, whether calculated for the subjects that completed the study (n=11), or including discontinued subjects (n=15). Changes from baseline were not statistically significant for the efficacy measures that were not designed for use in PTHS but have been used in other neurodevelopmental conditions. Results for efficacy measures specifically designed for Pitt Hopkins syndrome The results for the global measures rated by both clinicians and caregivers showed a level of improvement considered clinically meaningful. 9 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Improvement (CGI-I), an assessment by the clinician of the child's overall status compared with baseline. The mean CGI-I score was 2.6. Five children received a score of either 1 ("very much improved") or 2 ("much improved"). 8 out of 11 children that completed the trial showed improvement measured by the PTHS Caregiver Overall Impression of Change (CIC), an assessment by the caregiver of the child's overall status compared with baseline. The mean CIC score was 3.0. Four children received a score of 2 ("much improved"). 6 out of 11 children that completed the trial showed improvement measured by the PTHS Clinical Global Impression of Severity (CGI-S), an assessment by the clinician of the child's overall severity of illness, compared with the assessment at baseline. The CGI-S score improved from 6 to 5 for 3 children and from 5 to 4 for 3 children. 8 out of 11 children that completed the trial showed improvement measured by the Caregiver Top 3 Concerns overall score, an individualised assessment by the caregiver of their child's most concerning symptoms. Language/Communication was the most commonly chosen concern. Detailed results are available in the full announcement and investor presentation: https://announcements.asx.com.au/asxpdf/20240527/pdf/063ysycd36ykzt.pdf https://announcements.asx.com.au/asxpdf/20240527/pdf/063ytmj3st1zr6.pdf About Pitt Hopkins syndrome Pitt Hopkins syndrome (PTHS) is a neurodevelopmental condition caused by the loss of one copy or a mutation of the TCF4 gene on chromosome 18. The incidence of PTHS has been estimated at between 1 in 34,000 and 1 in 41,000 people. Characteristics of PTHS are a range of developmental delay with moderate-to-severe intellectual disability and behavioral differences, hyperventilation and/or breath-holding while awake, seizures, gastrointestinal issues, lack of speech, sleep disturbance, stereotypic hand movements and distinctive facial features. Some individuals with PTHS are diagnosed with autism. Further information about PTHS is available at: www.pitthopkins.org About Neuren Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. Recognising the urgent unmet need, all programs have been granted "orphan drug" designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases. DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide. Neuren's second drug candidate, NNZ-2591, is in Phase 2 development for multiple neurodevelopmental disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome and Pitt Hopkins syndrome. ASX Listing Rules informationThis announcement was authorized to be given to the ASX by the board of directors of Neuren Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124 Forward-looking Statements This announcement contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements in this announcement.
GUANGZHOU, China, May 27, 2024 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced its board of directors has increased its share repurchase authorization to US$30.0 million, expanding the USD$20.0 million share repurchase authorization granted in March 2022, commencing on May 27, 2024. In March 2022, the Company's board of directors authorized a share repurchase program under which the Company may repurchase up to US$20.0 million of its ordinary shares in the form of American depositary shares ("ADSs") during a period of up to 12 months. In March 2023, the Company's board of directors has authorized to extend such plan for another 12 months commencing on March 16, 2023, and in March 2024, the Company's board of directors has authorized to extend such plan for another 24 months commencing on March 16, 2024. As of May 27, 2024, CNFinance has repurchased approximately US$18.5 million of its ADSs. About CNFinance Holdings Limited CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company") is a leading home equity loan service provider in China. CNFinance, through its operating subsidiaries in China, conducts business by connecting demands and supplies through collaborating with sales partners and trust companies as well as commercial banks. Sales partners are responsible for recommending micro- and small-enterprise ("MSE") owners with financing needs to the Company and the Company introduces eligible borrowers to licensed financial institutions with sufficient funding sources including trust companies and commercial banks who will then conduct their own risk assessments and make credit decisions. The Company's primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities and other major cities in China. The Company's risk mitigation mechanism is embedded in the design of its loan products, supported by an integrated online and offline process focusing on risks of both borrowers and collateral and further enhanced by effective post-loan management procedures. For more information, please contact: CNFinanceE-mail: ir@cashchina.cn
GUANGZHOU, China, May 27, 2024 /PRNewswire/ -- News report from GDToday Organized by Guangdong, Hong Kong SAR and Macao SAR, the Guangdong-Hong Kong-Macao Greater Bay Area and Europe (France) Economic and Trade Cooperation Conference was held in Paris on May 24 (local time). More than 400 representatives from French industrial and commercial circles attended the conference. "This is a very important event, which put in contact with different companies, even new companies," said Gilles-Henry Garault, Vice-President and President of the International Commission, Encouragement Society for Industry in France. He indicated that the GBA can be one of the first economic centers in the world. At present, about 1/3 of the French companies in China have chosen to settle in Guangdong, including EDF Energy, Danone and Sanofi. In Garault's opinion, the GBA is the first choice for foreign companies to enter China. According to the data published by Guangdong Sub-Administration of General Administration of Customs of China, in Q1 this year, trade volume between France and the province of Guangdong reached 24.86 billion RMB, increasing 11.1% year-on-year. "I have been to the GBA many times since I became the CEO of Airbus China in 2003." said Norbert Ducrot, President of Wavelandes, "I discovered that the GBA is a fantastic region with a huge population and market. This year is very important because it's the 60th anniversary of the diplomatic ties between China and France." In the beginning of May, both China and France made a joint declaration on enhancing global governance cooperation on artificial intelligence. According to a ranking published by the World Intellectual Property Organization, the Shenzhen-Hong Kong-Guangzhou science and technology cluster has been listed the second for the past 4 years. Ducrot indicated that the GBA is the best place for both France and China to launch projects in the fields of software and hardware, electronics domains, and artificial intelligence, as this region has developed tech businesses and abundant resources of talents. "The conference reflects the remarkable achievement of economic development in China," said Roger Sebbagh, Special Adviser of French President. He indicated that he would like to play a role in bridging France and China in the future. In his opinion, cooperation between France and China is a win-win cooperation and he believes that the collaboration will bring positive influence to other countries and promote their development. According to preliminary statistics, 36 bilateral investment and trade cooperation projects between France (and Europe) and Guangdong, Hong Kong and Macao are reached with a total value of 3.22 billion US dollars in this conference. Among them, France (and Europe) will invest 1.59 billion US dollars in the GBA, while the GBA will invest 1.47 billion US dollars in France (and Europe).
BALI, Indonesia, May 27, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn: An English-language publication highlighting President Xi Jinping's insights into water governance has been well received by international experts, who noted its potential in offering solutions to countries grappling with a water crisis exacerbated by climate change. Photo taken on Sept 2, 2023 shows the Datengxia water resources management facility in Southwest China. [Photo/Xinhua] The experts shared their observations during the eight-day 10th World Water Forum, which concluded on Saturday in Bali, Indonesia. The event featured the launch on Tuesday of the book Water Governance in China: Perspectives of Xi Jinping. One of the key parts of the book is an innovative philosophy on water governance that Xi proposed in 2014. It focuses on "prioritizing water conservation, balancing spatial distribution, adopting systematic approaches and leveraging the roles of both government and market". The president stressed that water governance includes multiple aspects, such as development and utilization, regulation and allocation, and conservation and protection. The key focus at present, in terms of mindset, awareness and action, is water conservation, and "we must prioritize water conservation to orchestrate a coordinated approach to water governance throughout the entire cycle", according to the book. Li Guoying, minister of water resources, says in the book's foreword that Xi, who is also general secretary of the Communist Party of China Central Committee, proposed the philosophy from the strategic perspective of achieving sustainable development for the Chinese nation. The president has also provided insights into a series of significant theoretical and practical issues, including why water issues should be addressed in the new era, and what should be done and how to do it, forming a body of new concepts, ideas and strategies for water governance, Li said. "Guided by his water governance principles, China has achieved historic successes and undergone transformative changes and improvements in water governance," the minister said, highlighting the country's capacity "to prevent floods and droughts, save, optimally allocate, and make efficient use of water resources, and protect and manage river and lake ecosystems". With only 6 percent of the world's freshwater resources, China has managed to ensure food and water security for nearly 20 percent of the global population, and has contributed more than 18 percent of the world's economic output, Li noted. Highlighting the book as the first systematic introduction to China's water governance principles and technologies, Li Lifeng, director of the Land and Water Division at the United Nations' Food and Agriculture Organization, said he believes it will contribute to the future water management practices of countries around the world. With a series of methods and concepts ranging from water conservation and storage to flood management, China has an array of practices that can be shared with other nations, he said. Philippe Gourbesville, president of the International Association for Hydro-Environment Engineering and Research, said the book "is presenting a strategy for China for addressing the main issues that are coming in the next decades, especially achieving water security". Nebiyou Kassahun, from the China Institute of Water Resources and Hydropower Research, who is a doctoral student majoring in hydrology and water resources, said, "The book gives a detailed description of philosophical aspects of water conservancy all over China, and I think that it is a good idea to share this with the rest of the world." "I also appreciate the fact that General Secretary Xi Jinping is able to emphasize these things, because it is actually a really current global issue, a global problem right now," he added. Pedro Liberato, former director-general of the department of international relations of Portugal's Ministry of Environment and Climate Action, lauded China's timely mindset on water governance. China's experiences in water resources management hold significant global relevance, particularly as the nation is adapting its water governance strategies to address evolving challenges posed by climate change, he said. "China has the experience that is very important to have at this moment," Liberato said, adding that the nation recognizes "that some of the good solutions 10 years ago are not the best ones anymore because of the extreme events".
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
